Published in Gene Therapy Weekly, September 21st, 2000
"HNSCs may serve as a cellular vehicle for molecular therapies as well as for cell replacement in the human central nervous system," wrote F.J. Rubio and colleagues, Autonomous University of Madrid. "The survival, integration, and differentiation of HNSC.100, a multipotent cell line of HNSCs (A. Villa et al., Exp Neurol, 2000;161:67-84), conditionally perpetuated by genetic and epigenetic means, was investigated after transplantation to the striatum and substantia nigra of the adult, intact rat brain."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly